Retatrutide

Retatrutide is a 39-amino-acid synthetic peptide engineered as a triple agonist of three incretin and metabolic receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. Developed by Eli Lilly and Company and currently in Phase 3 clinical trials, retatrutide represents the first-in-class triple agonist mechanism in metabolic peptide therapeutics — a step beyond the dual GLP-1/GIP agonism of tirzepatide and the GLP-1-only agonism of semaglutide. Phase 2 results published in the New England Journal of Medicine in 2023 documented mean weight reductions of approximately 24% at the highest dose over 48 weeks, drawing significant attention from the broader endocrinology and metabolic research communities.

It is sold for laboratory and analytical research only and is not approved by the U.S. Food and Drug Administration for any therapeutic indication. Retatrutide is currently an investigational compound under active clinical development by its originator and is not available through pharmaceutical channels.

Molecular Structure and Stability

Retatrutide is a 39-amino-acid linear peptide modified with a fatty acid moiety attached via a linker, similar in design strategy to tirzepatide and semaglutide — the fatty acid extends plasma half-life through albumin binding, enabling weekly dosing schedules in clinical trial protocols. Its molecular weight is approximately 4,731 Daltons, and its amino acid sequence has been deliberately engineered to balance binding affinity across all three target receptors (GLP-1, GIP, and glucagon) — a non-trivial pharmacological challenge given the structural overlap between these receptor families.

The lyophilized (freeze-dried) form supplied for research is stable at -20°C for up to 24 months when sealed and protected from moisture. Following reconstitution with bacteriostatic water, the compound retains research-grade integrity for approximately 30 days when refrigerated at 2–8°C and protected from light. Repeated freeze-thaw cycles should be avoided to maintain experimental reproducibility.

Mechanism of Action — Triple Agonism in Human Metabolic Physiology

Retatrutide's pharmacological design is built on three distinct receptor pathways, each with established roles in human metabolism. The clinical hypothesis driving the compound's development is that simultaneous activation of all three pathways produces additive — and potentially synergistic — effects beyond what any single or dual agonist can achieve.

GLP-1 receptor agonism. Glucagon-like peptide-1 receptor activation produces glucose-dependent insulin secretion, suppression of glucagon release, slowed gastric emptying, and central appetite suppression mediated through hypothalamic and brainstem nuclei. This is the validated mechanism behind a class of FDA-approved diabetes and obesity therapeutics including liraglutide, semaglutide, and the GLP-1 component of tirzepatide. In retatrutide, GLP-1 agonism contributes to glycemic control and appetite reduction.

GIP receptor agonism. Glucose-dependent insulinotropic polypeptide is a second incretin hormone with effects on insulin sensitivity, lipolysis in adipose tissue, and energy expenditure. The role of GIP in metabolic regulation was historically debated, but tirzepatide's clinical success demonstrated that GIP agonism, when combined with GLP-1 activity, produces metabolic benefits beyond GLP-1 alone. Retatrutide preserves this dual incretin foundation.

Glucagon receptor agonism — the differentiating mechanism. Glucagon receptor activation, when carefully balanced against incretin effects, increases hepatic glucose output (counter to glucose-lowering effects from incretin agonism) but also significantly increases energy expenditure, hepatic fat oxidation, and lipolysis. The net metabolic effect — when glucagon agonism is combined with GLP-1 and GIP — has been hypothesized to produce greater weight loss than dual agonism alone, particularly through mechanisms targeting hepatic fat content and basal metabolic rate. This is the differentiating mechanism that distinguishes retatrutide from earlier-generation incretin compounds.

Hepatic fat metabolism. The glucagon component of retatrutide's pharmacology has particular relevance to liver fat content — a major area of unmet medical need in human metabolic medicine. Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) affects an estimated 5% of U.S. adults and currently has limited pharmacological treatment options. Phase 2 retatrutide data documented substantial reductions in liver fat content alongside weight loss, generating interest in the compound's potential MASH applications.

Adipose tissue and energy expenditure. Research in human adipocytes and adipose tissue from clinical trial participants has examined retatrutide's effects on lipolysis, adipocyte differentiation, and resting energy expenditure. The combined GIP + glucagon mechanism is hypothesized to drive greater lipolytic activity than incretin-only compounds.

Cardiovascular and renal pathways. Like other incretin-based compounds, retatrutide's effects on vascular function, blood pressure, and renal handling are being characterized through ongoing clinical research. The cardiovascular and renal implications of triple agonism remain an active research question.

Human Clinical Research

Retatrutide has progressed through Phase 1 and Phase 2 clinical trials and is currently in multiple Phase 3 programs. The published clinical literature is substantial relative to the compound's investigational status.

Phase 2 obesity trial (TRIUMPH program precursor). Published in the New England Journal of Medicine in June 2023, this 48-week trial in 338 adults with obesity (without diabetes) documented mean weight reductions of approximately 24% from baseline at the highest tested dose (12 mg weekly), with consistent dose-response across 1, 4, 8, and 12 mg arms. Placebo arm participants experienced a 2.1% weight reduction. The magnitude of weight loss exceeded that observed in pivotal trials for tirzepatide and substantially exceeded earlier GLP-1-only compounds, generating significant attention in the obesity medicine community.

Phase 2 Type 2 diabetes trial. Also published in 2023, this trial documented HbA1c reductions and weight loss in patients with Type 2 diabetes, supporting retatrutide's diabetes development pathway alongside the obesity program.

Phase 2 MASH trial. A dedicated Phase 2 trial in patients with biopsy-confirmed MASH has examined retatrutide's effects on liver fat content, fibrosis biomarkers, and hepatic inflammation, with early results suggesting substantial hepatic benefit alongside metabolic improvements.

Ongoing Phase 3 program (TRIUMPH). The TRIUMPH Phase 3 program includes trials evaluating retatrutide in obesity, Type 2 diabetes, obstructive sleep apnea, and cardiovascular outcomes. Full readouts are expected over the next several years and will inform potential FDA submission and approval pathways.

Comparative context. Retatrutide's Phase 2 weight-loss outcomes have been frequently compared to those of tirzepatide (SURMOUNT-1: ~22.5% at 72 weeks at highest dose) and semaglutide (STEP-1: ~14.9% at 68 weeks at highest dose). While direct head-to-head trial data is limited, the cross-trial comparisons have driven substantial research interest in triple agonism as a pharmacological class.

Retatrutide is among the most clinically-discussed investigational peptides in metabolic medicine and provides researchers studying triple-agonist receptor pharmacology with a well-characterized reference compound. The translation from preclinical mechanism to large-scale Phase 3 outcomes remains in progress, and researchers should consult primary literature for the most current clinical status.

Quality Verification — What Our COA Documents

Every batch of retatrutide supplied by Elara is independently analyzed by a third-party laboratory before release. Our Certificate of Analysis documents two distinct verification measures:

HPLC purity (≥99%). High-performance liquid chromatography separates the synthesized peptide from synthesis-related impurities, truncation sequences, and degradation products. Our specification requires a minimum 99% purity at the main peak. Retatrutide synthesis is technically demanding — the 39-amino-acid length combined with the fatty acid modification and the requirement for balanced affinity across three receptors makes purity verification particularly important for research reproducibility.

Mass spectrometry identity confirmation. MS analysis confirms that the molecular weight of the peak compound matches the theoretical molecular weight of retatrutide (~4,731 Da), verifying both structural identity and the absence of significant mass-shift modifications. For a compound of this complexity, mass spectrometry is the definitive identity test.

The COA accompanies every shipment and is also available for download on this product page.

Reconstitution and Handling for Research

For laboratory research applications, retatrutide is typically reconstituted using bacteriostatic water (0.9% benzyl alcohol). Standard practice involves slow addition of solvent along the inside wall of the vial — never directly onto the lyophilized powder, which can cause aggregation. The vial is then gently swirled (not shaken or vortexed) until the peptide is fully dissolved.

Once reconstituted, the solution should be stored at 2–8°C, protected from light, and used within 30 days for optimal molecular integrity. Sterile technique is essential during all handling steps. Researchers performing in vitro work or animal model studies should refer to their institution's IACUC protocols and standard handling guidelines specific to their experimental design.

Frequently Asked Questions

What is retatrutide?
Retatrutide is a synthetic 39-amino-acid peptide engineered as a triple agonist of the GLP-1, GIP, and glucagon receptors. It was developed by Eli Lilly and Company and is currently in Phase 3 clinical trials for obesity, Type 2 diabetes, MASH (liver disease), and obstructive sleep apnea. It is not currently FDA-approved for any indication.

How is retatrutide different from tirzepatide and semaglutide?
The compounds differ in receptor targets and pharmacological mechanism. Semaglutide (Ozempic, Wegovy) targets the GLP-1 receptor only — it is a single-receptor agonist. Tirzepatide (Mounjaro, Zepbound) targets both GLP-1 and GIP receptors — it is a dual agonist. Retatrutide targets GLP-1, GIP, and glucagon receptors — it is a triple agonist. The addition of glucagon receptor activation is the differentiating mechanism, hypothesized to enhance hepatic fat metabolism and energy expenditure beyond what dual agonism produces. Phase 2 weight-loss outcomes for retatrutide have been numerically greater than those reported for tirzepatide and semaglutide in their respective pivotal trials, though direct head-to-head comparison data is limited.

Has retatrutide been studied in humans?
Yes, extensively. Retatrutide has completed Phase 1 and Phase 2 clinical trials in obesity, Type 2 diabetes, and MASH, with results published in peer-reviewed journals including the New England Journal of Medicine. The compound is currently in multiple Phase 3 trials (the TRIUMPH program). Researchers should consult primary literature for the most current clinical trial status and outcomes.

What does HPLC ≥99% purity actually mean?
High-performance liquid chromatography is the analytical standard for assessing peptide purity. A specification of ≥99% indicates that, of all UV-detectable species in the analyzed sample, at least 99% of the integrated peak area corresponds to the target compound. For complex peptides like retatrutide, achieving and verifying 99%+ purity is particularly important because synthesis impurities can include closely related sequence variants that affect research reproducibility.

How long is retatrutide stable after reconstitution?
Reconstituted retatrutide retains research-grade integrity for approximately 30 days when stored refrigerated at 2–8°C and protected from light. Avoid freeze-thaw cycles. Lyophilized (unreconstituted) retatrutide is stable at -20°C for up to 24 months when properly sealed.

What human pathways does retatrutide research target?
The most-studied pathways with direct human clinical relevance include the three primary receptor systems (GLP-1, GIP, and glucagon), central appetite regulation, hepatic fat metabolism (relevant to MASH research), adipose tissue lipolysis, energy expenditure, and emerging research into cardiovascular and renal effects. The triple-agonist mechanism is itself an active area of pharmacological research.

Is retatrutide FDA-approved?
No. Retatrutide is currently an investigational compound in Phase 3 clinical trials and has not received FDA approval for any indication. It is not available through pharmaceutical channels and remains in active clinical development by its originator. Approval timelines depend on Phase 3 trial outcomes and regulatory submission processes.

Does Elara test every batch?
Yes. Every production batch of retatrutide receives independent third-party HPLC and mass spectrometry analysis before release. Batches that do not meet our 99% purity specification are rejected. The COA documenting analytical results for the specific batch you receive is included with every shipment and available for download above.